538 related articles for article (PubMed ID: 25989418)
1. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
[TBL] [Abstract][Full Text] [Related]
2. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model.
Dabaghian M; Latifi AM; Tebianian M; NajmiNejad H; Ebrahimi SM
Vaccine; 2018 May; 36(20):2886-2895. PubMed ID: 29627234
[TBL] [Abstract][Full Text] [Related]
3. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.
Dabaghian M; Latify AM; Tebianian M; Nili H; Ranjbar AR; Mirjalili A; Mohammadi M; Banihashemi R; Ebrahimi SM
Vet Microbiol; 2014 Nov; 174(1-2):116-26. PubMed ID: 25293397
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge.
Shokouhi H; Farahmand B; Ghaemi A; Mazaheri V; Fotouhi F
Virus Res; 2018 Jun; 251():40-46. PubMed ID: 29730305
[TBL] [Abstract][Full Text] [Related]
6. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and protective efficacy of recombinant M2e.Hsp70c (Hsp70(359-610)) fusion protein against influenza virus infection in mice.
Attaran H; Nili H; Tebianian M
Virol Sin; 2014 Aug; 29(4):218-27. PubMed ID: 25160757
[TBL] [Abstract][Full Text] [Related]
8. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice.
Alvarez P; Zylberman V; Ghersi G; Boado L; Palacios C; Goldbaum F; Mattion N
Vaccine; 2013 Jan; 31(5):806-12. PubMed ID: 23246552
[TBL] [Abstract][Full Text] [Related]
9. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
[TBL] [Abstract][Full Text] [Related]
10. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
11. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
[TBL] [Abstract][Full Text] [Related]
12. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine.
Jazi MH; Dabaghian M; Tebianian M; Gharagozlou MJ; Ebrahimi SM
Virus Res; 2012 Aug; 167(2):219-25. PubMed ID: 22609252
[TBL] [Abstract][Full Text] [Related]
13. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
Wang W; Huang B; Wang X; Tan W; Ruan L
Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
15. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
[TBL] [Abstract][Full Text] [Related]
16. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
[TBL] [Abstract][Full Text] [Related]
17. Characterization of immunity induced by M2e of influenza virus.
Wu F; Huang JH; Yuan XY; Huang WS; Chen YH
Vaccine; 2007 Dec; 25(52):8868-73. PubMed ID: 18061317
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens.
Zhang X; Liu M; Liu C; Du J; Shi W; Sun E; Li H; Li J; Zhang Y
Intervirology; 2011; 54(5):290-9. PubMed ID: 21228535
[TBL] [Abstract][Full Text] [Related]
19. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
[TBL] [Abstract][Full Text] [Related]
20. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y
Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
